Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
about
Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Vancomycin displays time-dependent eradication of mature Staphylococcus aureus biofilms.Prophylactic antibiotic administration for post cardiothoracic surgery sternal wounds: a retrospective studyEvaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunctionA pre-postintervention study to evaluate the impact of dose calculators on the accuracy of gentamicin and vancomycin initial doses.Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrationsUnderestimation of the calculated area under the concentration-time curve based on serum creatinine for vancomycin dosing.Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years.Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Assessment of Appropriateness of an Initial Dosing Regimen of Vancomycin and Development of a New Dosing Nomogram.Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons.Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.Therapeutic drug monitoring in the past 40 years of the Journal of Antimicrobial Chemotherapy.Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals.Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration.Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.Introducing MINA--The Molecularly Imprinted Nanoparticle Assay.Development and validation of a novel vancomycin dosing nomogram for achieving high-target trough levels at 2 canadian teaching hospitals.Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths).Intrawound Vancomycin powder as the prophylaxis of surgical site infection after invasive spine surgery with a high risk of infection.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Decreased vancomycin clearance in patients with congestive heart failure.Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.Antimicrobial AgentsVancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
P2860
Q34026240-0D301B27-7029-4616-86FB-DA112FEE55C9Q34526414-C8820660-7A6B-4DEF-8E4F-EDFE18EDE7E0Q35238093-DB4437B8-48D1-41CD-983C-B11A86D26DFEQ35676081-E48423E2-F2C8-415E-B6E2-97F6C619117AQ35691717-99359B0B-4812-42DA-BA23-166218ABAAE5Q36536339-1893D75D-D81A-42E5-97A0-37FB241BA222Q37673492-61173CDB-9573-46BC-8026-2DC8314C1461Q37989803-FE1083BB-E318-479D-A77C-E438362DBFFAQ38000242-C4D26D79-4CAA-44DC-A4BC-5F9B3844EDA0Q38137251-23FA3555-7D4D-4149-85E4-265799FD64EEQ38258649-797BEFAE-2601-48FF-BC84-060C82D80E71Q38611726-7E255E07-6D4A-4740-8B64-F22CF5788D04Q38818376-DDFAA0B0-1DE4-414F-875D-06F5335291E9Q38825167-A7A50061-2350-4D90-9955-81994DFF80F2Q39011332-12844B7E-814E-4726-88AD-119C62141792Q39375881-3EE59968-6834-4223-884C-EB799ECDBE3EQ40076368-EDB2D948-61E9-4A8C-93F5-EA42FE9E35C3Q40321062-C7344744-67F5-4D25-8B76-23392679DD63Q41861662-6CD3EB63-8361-49D8-BF88-98E3B8E2B1EEQ42209082-AE633BF3-8CE7-4B63-BE6F-E86BFA812DC4Q42334642-F243AE70-B1A2-4DEC-AEE0-9D4E30E14B95Q47123289-0B7EA0DF-8725-4B8B-AA34-8E07718D542BQ48197188-686FE177-7A17-481A-A765-9D091A16B18DQ51344353-C4BB8A01-8927-4696-8511-265BD1A09EFDQ53654914-227BE147-2201-4DD8-A0C5-D03577ACE826Q57549163-E664402F-93E8-4A4F-8519-35C1C2E7AFC5Q58699337-635C6138-3681-4733-AFB6-697D17188E9F
P2860
Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Development and evaluation of ...... eve new target concentrations.
@ast
Development and evaluation of ...... eve new target concentrations.
@en
Development and evaluation of ...... eve new target concentrations.
@nl
type
label
Development and evaluation of ...... eve new target concentrations.
@ast
Development and evaluation of ...... eve new target concentrations.
@en
Development and evaluation of ...... eve new target concentrations.
@nl
prefLabel
Development and evaluation of ...... eve new target concentrations.
@ast
Development and evaluation of ...... eve new target concentrations.
@en
Development and evaluation of ...... eve new target concentrations.
@nl
P2093
P356
P1476
Development and evaluation of ...... ieve new target concentrations
@en
P2093
P304
P356
10.1093/JAC/DKP085
P407
P577
2009-03-19T00:00:00Z